Maximum Dose of Tranexamic Acid
For trauma and hemorrhage, the maximum recommended dose is 2g IV total (1g loading dose over 10 minutes, followed by 1g infused over 8 hours), administered within 3 hours of injury or bleeding onset. 1, 2, 3
FDA-Approved Dosing (Hemophilia/Dental Procedures)
The FDA label specifies 10 mg/kg IV 3-4 times daily for 2-8 days as the approved regimen for hemophilia patients undergoing dental procedures 4. This translates to a maximum daily dose of approximately 40 mg/kg or roughly 3g per day for a 75kg adult when given four times daily.
Context-Specific Maximum Doses
Trauma & Major Hemorrhage
The 2g total dose is the established maximum based on the landmark CRASH-2 trial protocol 1, 2:
- 1g IV bolus over 10 minutes (loading dose)
- 1g IV infusion over 8 hours (maintenance)
- Critical timing: Must be given within 3 hours of injury; administration beyond 3 hours may increase mortality risk 1
The European trauma guidelines strongly endorse this regimen, emphasizing that tranexamic acid should not await laboratory results and should be administered immediately upon hospital admission for bleeding patients 2.
Postpartum Hemorrhage
- 1g IV over 10 minutes (first dose)
- Second 1g dose may be given if bleeding continues after 30 minutes or restarts within 24 hours
- Must be administered within 3 hours of birth for efficacy
Higher Dose Regimens (Limited Evidence)
The HALT-IT trial investigated a high-dose regimen of 4g total (1g loading + 3g over 24 hours) for gastrointestinal bleeding but found no mortality benefit and increased venous thromboembolism risk (0.8% vs 0.4%, RR 1.85) 6. This argues against exceeding the standard 2g total dose.
The STAAMP trial suggested up to 3g total with repeated dosing in hypotensive trauma patients 1, but this remains investigational and is not standard practice.
Route-Specific Considerations
Intravenous
- Standard maximum: 2g total over 8-10 hours
- Infusion rate: No faster than 1 mL/min (100 mg/min) to avoid hypotension 4
- For IV use only: Intrathecal administration causes seizures and cardiac arrhythmias 4
Oral
- Hereditary angioedema prophylaxis: 1g twice daily (2g/day maximum) 7
- Melasma treatment: 750 mg/day (250mg three times daily) for 12 weeks 8
Renal Dose Adjustments
Mandatory dose reductions for renal impairment 4:
| Serum Creatinine | Adjusted Dose |
|---|---|
| 1.36-2.83 mg/dL | 10 mg/kg twice daily |
| 2.83-5.66 mg/dL | 10 mg/kg once daily |
| >5.66 mg/dL | 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours |
Critical Safety Warnings
Absolute contraindications 4:
- Active intravascular clotting
- Subarachnoid hemorrhage (risk of cerebral edema/infarction)
- Hypersensitivity to tranexamic acid
Dose-dependent seizure risk: Higher doses (>2g) are associated with increased seizure risk, particularly in cardiac surgery 9. This is a strong argument against exceeding standard dosing.
Thromboembolic risk: Avoid concomitant use with pro-thrombotic agents (Factor IX concentrates, hormonal contraceptives) 4. The HALT-IT trial demonstrated increased VTE risk with high-dose regimens 6.
Practical Dosing Algorithm
- Trauma/major hemorrhage with shock: 1g IV bolus + 1g over 8h (within 3h of injury) 1, 2
- Postpartum hemorrhage: 1g IV, repeat once if needed (within 3h of birth) 3
- Cardiac surgery high bleeding risk: 30 mg/kg bolus + 16 mg/kg/h + 2 mg/kg priming 9
- Renal impairment: Reduce per table above 4
- Beyond 3 hours post-injury/birth: Do not administer—no benefit and potential harm 1, 3
The evidence strongly supports 2g total as the maximum safe and effective dose for acute hemorrhage control, with higher doses offering no additional benefit and increased thrombotic risk.